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1. Introduction 
Treatment of stress urinary incontinence (SUI) caused by urethral hypermobility or intrinsic 
sphincter deficiency with urethral sling procedures may yield up to a 80-90% success rate 
depending on the definition of success. (Nilsson et al. 2001; Liapis et al. 2002; Rodriguez & Raz 
2003; Nilsson et al. 2004; Ward & Hilton 2004) In a minority of patients, however, there is 
persistence or worse incontinence after surgical therapy. In the general population, risk factors 
for midurethral sling (MUS) failure are BMI >25, mixed incontinence, intrinsic sphincter 
deficiency, diabetes mellitus, advanced patient age >75 years old and prior continence surgery. 
(Cammu et al. 2009; Stav et al. 2010) Potential surgery related reasons for failure include 
improper adjustment of the sling or misplacement of the suburethral tape. Female patients 
with urethral incompetence and severe incontinence due to multiple failed surgeries, 
neurologic injury, or congenital anomalies represent a unique surgical challenge.  
Patients with neurologic conditions have sacral arc lesions with paralysis of the skeletal 
musculature and an open urethra. All other patients who have failed multiple sling and 
anti-incontinence procedures may have severe symptoms of SUI and an open urethra with a 
low valsalva leak point pressure. These patients often have an incompetent, difficult to 
compress, urethra likely due to a combination of urethral denervation, and violation of the 
periurethral fascia, as well as their underlying risk factors for SUI. (Bump & Norton 1998) 
These patients have been shown to have low chances of cure after repeat anti-incontinence 
surgery and be more likely to suffer from complications including retention, osteomyelitis, 
and pelvic abscess. (Petrou & Frank 2001) 
In the recurrent or refractory stress urinary incontinence female patient, a routine sling 
procedure providing only posterior support will not typically yield an appropriate 
response. Management options include repeat placement of a “tight” pubovaginal sling or 
replacement of a different type of sling, a spiral sling, periurethral bulking agents, 
adjustable continence therapy (ACT) device and the artificial urinary sphincter (AUS) prior 
to bladder neck closure with continent urinary diversion. This manuscript will review the 
evaluation and management options for recurrent stress urinary incontinence in this 
challenging population.  
2. Evaluation 
There are a significant number of patients in the United States that undergo successful sling 
placement for SUI, however a minority will present with persistent or recurrent 
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incontinence. Recurrent stress urinary incontinence after urethral sling surgery (transvaginal 
tape and transobturator tape) and common complications such as urinary tract infection and 
de novo urge urinary incontinence need to be fully evaluated. It is also important when 
determining the etiology of surgical failure to identify whether the patient has refractory 
SUI by determining whether there was any period of cure or improvement. Recurrent stress 
urinary incontinence warrants at a minimum: complete history and physical examination 
and urinalysis. Most physicians would advocate urodynamic testing in cases of failed 
previous surgery for incontinence. (Houwert et al. 2010; Walsh & Moore 2010)  Cystoscopic 
evaluation is easy to perform in the clinic and should be utilized to determine if there is 
evidence of sling erosion or misplacement. Ultimately, the determination must be made 
whether this leakage is due to bladder or outlet dysfunction.   
If there is evidence of flank or pelvic pain, a retroperitoneal ultrasound with evaluation of 
the bladder is necessary to evaluation for obstruction and or injury to the ureteral orifices. 
Urodynamics with or without fluoroscopy is useful to further characterize the physiology of 
the bladder. While there is no published data regarding routine use, most practices use 
routine urodynamic evaluation of failed anti-incontinence patients prior to a repeat 
procedure. (Rutman et al. 2006; Rodriguez et al. 2010; Walsh & Moore 2010) 
Some urologists routinely use dynamic T2-weighted MRI to look at the anatomic defects 
seen in pelvic floor dysfunction. A vaginal examination might demonstrate a change in the 
patient’s pelvic floor anatomy, such as evidence of prolapse. Many researchers have used 
dynamic MRI to evaluate the female pelvis and delineate the possible components of pelvic 
floor dysfunction. This requires experience using this modality and a radiologist that can 
interpret the test in a useful way. In the cost-saving climate of health care today, dynamic T2 
MRI can likely only be used in the setting of severe refractory incontinence or neurologic 
conditions. 
3. Nonsurgical management 
There is a paucity of literature for the nonsurgical management of recurrent SUI following 
prior surgical repair. Most treatments are based on primary SUI studies, namely pelvic floor 
muscle training, weight loss, incontinence pessary and medications. These options have 
been systematically reviewed elsewhere. (Shamliyan et al. 2008) 
4. Periurethral bulking agents 
While the majority of patients that have failed surgical repair for SUI will opt for a more 
aggressive intervention, periurethral bulking agents offer a potential adjunct for the 
insufficient sling, especially if the patient or surgeon are hesitant to be more invasive given 
the history of prior urethral surgery. Periurethral bulking agents include biodegradable and 
nonbiodegradable agents that are injected endoscopically in the perurethral tissue to 
presumably further coapt the urethral mucosa. While the availability of these agents has 
recently changed, the primary injectable bulking agents in the United States include 
Contigen (Bard Inc., Murry Hill, NJ) which has recently been discontinued, Durasphere 
(Coloplast Inc, Minneapolis, MN), Macroplastique (Uroplasty Inc, Minneapolis, MN) and 
Coaptite (Bioform Inc., Franksville, WI).   
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Investigators have reported the use of periurethral bulking agents after failed sling procedures 
for SUI, but no randomized studies have been reported. However, a recent report looking at 
intermediate follow up has reported some success. Macroplastique and Durasphere were used 
as periurethral bulking agents in 23 women following a failed midurethral sling procedure. 
(Lee et al. 2010) Macroplastique was used in 21 patients and Durasphere was used in 2 patients 
with a median interval between sling placement and periurethral bulking agent injection of 12 
months (range 3-65). With intermediate follow up at a median of 10 months (range 6-34 
months), 8 of 23 patients (35%) of all patients reported “cure” whereas 92% reported they had 
benefited from the procedure. Notably, 77% of the women reported satisfaction from the 
procedure, perhaps noting the relative simplicity and ease of placement.    
5. Revision urethral sling surgery 
The literature is maturing with regard to the appropriate choice for a repeat sling following 
midurethral sling for SUI. Stav and colleagues reviewed the cases of 1225 retrospectively 
identified women who underwent either a retropubic or transobturator sling. 91% of these 
patients completed a telephone interview questionnaire. (Stav et al. 2010) The majority of 
these women had a retropubic sling as opposed to a transobturator sling. Mean follow up 
was 50 months. Their re-operation rate for failure was 14%. Repeat retropubic sling 
placement was significantly more successful than utilizing a transobturator approach (71% 
vs 48%, p=0.04). Repeat slings were placed without removal of the previous sling. Most 
surgeons will opt to use a retropubic sling for recurrent incontinence and rather than a 
transobturator sling because of the greater urethral tension generated. Management options 
also include repeat placement of a “tight” pubovaginal sling with the intent of putting the 
patient in urinary retention. This can be done utilizing autologous fascia as well.  
6. Adjustable Continence Therapy (ACT) system 
The efficacy, safety & technical feasibility of the ACT was initially reported in 2009 as a 
novel device for the treatment of recurrent female SUI. (Aboseif et al. 2009) The device is 
intended to be a minimally invasive implantable device that provides support at the 
urethrovesical junction and enhances urethral coaptation. Its unique advantage is that it is 
also adjustable allowing for further optimization of the device post-operatively.  
Placement of the ACT device is via bilateral small incisions between the labia majora and 
minora at the level of the urethral meatus with a specially designed trocar. Fluoroscopic and 
digital guidance is used to identify a point just distal to the urethrovesical junction where 
the balloons are placed. The balloons are then inflated with 1-1.5 mL of  isotonic contrast 
solution. The subcutaneous inflation ports are then placed in a pocket in a superior ventral 
portion of each labia majora and the skin is closed with subcuticular absorbable suture. 
(Aboseif et al. 2009; Kocjancic et al. 2010)  
The initial experience with the ACT system showed a complication rate of 24.4% (38 of 156 
patients). Complications included port erosion, urinary retention, balloon erosion or 
migration and worsening incontinence. 18.3% (28 of 153) of patients underwent explantation 
within the first year, however 50% of explanted cases then underwent replacement. Since 
the development of the device, improvement in the technical related learning curve has led 
to reduced rates of complications.  
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At a mean follow-up of 72 months (range 12-84), 68% of patients (n=29) reported themselves 
dry. (Kocjancic et al. 2010) All of these patients had at least one prior pelvic surgery for SUI. 
The researchers reported 12 month urodynamic data (n=30 patients) which showed a 
statistically significant increase in VLPP from a mean baseline of 51.06  24.38 to 86.0  21.44 
cm H2O (p<0.01). Complications requiring device removal developed in 21.1% of patients.   
Most recently, Aboseif and colleagues presented a series of 89 patients with the ACT device. 
(Aboseif et al. 2011) They reported that 47% of the patients were dry at 1 year and 92% 
overall were subjectively improved. Pads per day and incontinence episodes were 
significantly improved, in addition to outcomes on standardized questionnaires. Their 
complication rate was similar to previously published studies with an explant rate of 21.7%. 
Proponents of the ACT device, that are proficient in placement and adjustment, report it is 
effective, simple and safe.  
7. Artificial urinary sphincter 
The AUS in the female population differs from the suburethral sling in that it does not 
provide a backboard or urethral support, but rather it attempts to mimic the sphincter 
mechanism of the urethra with circumferential compression. (Light & Scott 1985) The initial 
use of the AUS in women with incontinence was described in 1985 (Light & Scott 1985) and 
has since been well documented in the literature. (Vayleux et al. 2011)  
Costa and colleagues evaluated the efficacy of the AMS 800 AUS in women with Type III 
incontinence and a negative Marshall test. (Costa et al. 2001) They described a modified 
surgical procedure through an abdominal approach. Of the 190 patients with working devices, 
continence was achieved in 88.7% and 81.8% of those with non-neurogenic and neurogenic 
bladders, respectively at a mean follow-up of 3.9 years. 51 patients had perioperative 
complications and a high percentage of patients had not undergone prior surgical therapy. 
Thomas and associates reported 12 year follow-up in 68 patients who underwent an AUS. 
(Thomas et al. 2002) Despite an 81% continence rate, 46% required removal or replacement for 
erosion or infection. They concluded by recommending an AUS in patients with SUI after 
failure of one anti-stress incontinence operation and rather than as a last resort. More recent 
series reports demonstrate the safety, efficacy and complication rates associated with female 
AUS implantation. (Chung et al. 2010; Vayleux et al. 2011) Importantly, while there is a high 
proportion of patients that continue to use the AUS after implantation, about 50% of them 
have required revision or replacement, usually within the first several years of implantation. 
Continence rate in these two studies indicates 65-70% for no pads and 73.5-83% for 0 to 1 pad 
per day.  Satisfaction rates were high with a majority of patients reporting they would undergo 
AUS placement again if necessary. Additional modifications such as insertion of an AUS 
laparoscopically (Roupret et al. 2010) or with a large cuff (Revaux et al. 2010) have been 
proposed, however long-term data is lacking at this time.   
8. Spiral sling procedure 
A newer technique initially described by Raz and colleagues is a transvaginal sling procedure 
in adult women that encircles the urethra providing circumferential coaptation. The spiral 
sling is a salvage procedure for a small, yet severe group of female patients with a totally 
incompetent urethra. The procedure was initially described in patients with congenital or 
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neurological diseases. (Rutman et al. 2006) It has more recently been described in patients with 
multiple failed surgeries for SUI. (Mourtzinos et al. 2008) The procedural details of the spiral 
sling are not widely published and will therefore be reviewed here in detail.   
Notable surgical steps different from other suburethral slings are as follows: Two parallel 
distal oblique incisions are made in the anterior vaginal wall. The retropubic space is 
entered and a complete urethrolysis is performed by detaching the urethropelvic ligaments 
from the arcus tendineous fascia pelvis and freeing all retropubic adhesions. The urethral 
dissection is started in the mid-urethral area just proximal to the pubo-urethral ligaments 
and carried proximally to free the rest of the urethra and the bladder neck. Then a 
suburethral tunnel is created in the anterior vaginal wall 1.5 cm from the urethral meatus. 
Polypropylene mesh measuring approximately 1 X 15 cm is passed dorsally, between the 
urethra and the pubis. The ends of the mesh are crossed ventrally through the previously 
made vaginal tunnel. This maneuver creates a complete circle of mesh around the urethra. A 
suprapubic puncture is made just above the symphysis and a double-pronged needle (Cook 
Urological, Inc., Spencer, IN) is passed under finger control through the fascia and 
retropubic space to the vaginal incision. The previously placed 0-polyglactin sutures from 
the polypropylene mesh are transferred to the suprapubic incision. This is repeated on the 
contralateral side and the sutures are tied without tension.  
Between August 1999 and October 2004, 47 patients underwent placement of a spiral sling. 
(Rutman et al. 2006) This initial patient population was initially selected because of 
congenital or neurologic diseases, however, the technique was later expanded to include 
those patients with multiple failed surgeries for SUI and an incompetent lead pipe urethra. 
Of the 47 patients, seven were lost to follow-up. The mean age of the remaining 40 patients 
was 59.0 years (23-86). This represented a complex cohort of patients with 98% having failed 
a prior anti-incontinence surgery. The patients had undergone a mean of 2.6 previous anti-
incontinence surgeries and used an average of 6 pads per day. There were two patients who 
had previous augmentation cystoplasty and were performing self-intermittent 
catheterization but had significant SUI between catheterizations. All patients were 
considered candidates for urethral closure and continent diversion as a salvage procedure. 
In this group of 40 patients, the average follow-up was 12 months (6-37). There were no 
intraoperative complications. The de-novo urge incontinence rate was 7.4%. Of the 27 patients 
with preoperative urge incontinence (UI), 9 (33%) had resolution of their symptoms with the 
procedure. One of the patients had persistent refractory UI and subsequently underwent a 
sacral neuromodulation procedure. No patient experienced de novo retention after the spiral 
sling. The four patients who were performing self-intermittent catheterization pre-operatively 
continued to do so after the procedure. There were no urethral or vaginal erosions. The mean 
number of pads decreased from 6.0 preoperatively to 0.9 postoperatively (P<0.005). 78% of 
patients reported improvements of 90% or greater. Patients reported a mean improvement of 
symptoms of 87% after surgery. Ultimately, three patients underwent bladder neck closure 
and continent augmentation and were considered failures. 
More recently, the spiral sling technique was described in 46 patients with multiple failed 
surgeries for SUI excluding patients with neurologic or congenital anomalies. (Mourtzinos, et 
al. 2008) The mean age of the study population was 62 years and the mean follow-up was 15 
months (6 to 45 months). All patients had failed a prior anti-incontinence surgery. There were 
no intraoperative complications and no cases of permanent urinary retention postoperatively 
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requiring transvaginal urethrolysis. On patient driven subjective assessment, 49% of patients 
reported never experiencing SUI, and 72% experienced no or rare episodes of SUI. Overall 
patients reported a mean improvement of 84% with a decrease in daily pads from 5.5 to 1.0. 
Most patients were highly satisfied with their urinary symptoms after surgery (mean QoL of 
1.4). In addition, there was no statistically significant difference between pre and postoperative 
symptoms of incomplete bladder emptying (P>0.05).  
A review of the literature for alternatives to bladder neck closure revealed no existing 
circumferential sling procedure in the adult population. Mingin and colleagues described a 
transabdominal technique of a urethral sling using rectus muscle wrapped around the 
urethra for pediatric patients with congenital urethral incompetence. (Mingin et al. 2002) Of 
the 37 patients reported, 92% remained dry between catheterizations. The pediatric 
population is unlike this population since these patients had roughly three anti-incontinence 
surgeries with subsequent scarring and more difficult coaptation. The mechanism of cure of 
the transvaginal spiral sling is not completely understood. It likely supports the midurethral 
segment while preventing urethral descent and improving pressure transmission to the 
urethra. In addition, unlike a routine sling procedure, the spiral sling also provides 
circumferential coaptation to the urethra at the time of increases in intrabdominal pressure.  
Raz and colleagues concluded that the spiral sling is an effective salvage transvaginal 
procedure that may be considered for a small subset of female patients with non-functional 
urethras as a last resort prior to urethral closure procedures. This includes patients with 
urethral incompetence caused by neurologic disease, congenital anomalies or iatrogenic 
injury from multiple failed anti-incontinence surgeries. The most comparable surgical 
alternative is the AUS which requires manual dexterity to operate the device and a more 
extensive dissection to implant all components. The initial outcomes look promising but 
longer follow-up will better define its role in refractory female incontinence and 
demonstrate the durability of the spiral sling. 
9. New technologies 
Efficacy, safety & technical feasibility of intrasphincteric injections of autologous muscle 
derived stem cells have been shown by several groups in both animal models and humans. 
(Mitterberger et al. 2008; Sebe et al. 2011) In the human studies, myoblasts and fibroblasts 
were obtained from muscle biopsies of the patient. Cells are then grown in a culture facility 
to yield more myoblasts. After amplification, the cells are collected and frozen in a pellet, 
which is transferred to the urologist and thawed immediately prior to endourethral injection 
under endoscopic control. A recent review of stem cells for the treatment of urinary 
incontinence nicely describes the theory behind the use of stem cells for the treatment of 
urinary incontinence. (Staack & Rodriguez 2011) Ideally, these autologous cells provide 
additional mucosal coaptation in order to restore resting urethral closing pressures. These 
studies are in their infancy and no data has been reported on women with refractory stress 
urinary incontinence, however this might provide a more effective means of endoscopic 
bulking without the use of collagen and other synthetic materials. 
10. Conclusion 
Traditional first-line therapies for stress urinary incontinence are not successful in all 
women and management of recurrent incontinence can be quite difficult. Options for these 
www.intechopen.com
 
Refractory Stress Urinary Incontinence 
 
239 
patients include conservative management, endoscopic management with periurethral 
bulking, a repeat sling procedure, spiral slings, the artificial urinary sphincter and adjustable 
continence therapy devices or new technologies such as autologous stem cell injection. 
Variable success rates for all of these methods have been reported in the literature 
depending on the length of follow up and the definition of cure.  
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